Search Results - subject:"Pfizer"

Evidence of abnormal trading on COVID-19 Pfizer vaccine development information

Mason, Andrew N.; Elkassabgi, Ahmed - In: Journal of Risk and Financial Management 15 (2022) 7, pp. 1-10

public announcements concerning COVID-19 vaccine developments on stock returns and volatilities for Pfizer, Moderna, and the … important public COVID-19 vaccine development announcements related to Pfizer and Moderna vaccines. This methodology was … COVID-19 vaccine development news was made public. Specifically, Pfizer stock returns were significantly higher (above the …

Persistent link: https://www.econbiz.de/10014332500

Evidence of abnormal trading on COVID-19 Pfizer vaccine development information

Mason, Andrew N.; Elkassabgi, Ahmed - In: Journal of risk and financial management : JRFM 15 (2022) 7, pp. 1-10

Persistent link: https://www.econbiz.de/10013370364

The success of divestitures in merger enforcement : evidence from the J&J-Pfizer transaction

Tenn, Steven; Yun, John M. - 2009

Persistent link: https://www.econbiz.de/10003829827

Patent Monopolies and the Costs of Mismarketing Drugs

Baker, Dean - Center for Economic and Policy Research (CEPR) - 2015

Patent monopolies have long been used as a mechanism for financing innovation and research. The logic is that the government awards a monopoly on a product or process for a limited period of time in order to reward innovation. However, in addition to providing incentives for innovation and...

Persistent link: https://www.econbiz.de/10011265862